Related by context. All words. (Click for frequent words.) 83 Receives Patent 81 Files Patent Application 80 Begins Shipment 80 Patent Covering 80 Awarded Patent 79 Commercializes 79 Announces FDA Clearance 78 Issued Patent 78 Announce License Agreement 78 Receives FDA Clearance 77 Files IND 77 Completes Enrollment 77 FDA Clears 77 Receives Orphan Drug Designation 76 Files Patent 76 Completes Patient Enrollment 75 Gets FDA Clearance 75 Announces Issuance 75 Develop Next Generation 75 Achieves Milestone 74 Introduces Revolutionary 74 Initiates Clinical Trials 74 Sign Licensing Agreement 74 Expand Collaboration 74 Sign License Agreement 74 Initiates Clinical Trial 74 Begins Shipping 74 Announces License Agreement 74 Announces Licensing Agreement 74 Strengthens Position 74 Announce Collaboration Agreement 73 Announces Immediate Availability 73 Announce Collaboration 73 Develops Innovative 73 Clinical Trial Results 73 Subsidiary Receives 73 Immunomedics Announces 73 Initiates Phase II 73 Develops Novel 73 Achieves Significant 73 Report Analyzes 73 Submits Application 73 Receives SFDA Approval 73 Introduces Breakthrough 73 FDA Approves 72 Awarded Patents 72 Patents Covering 72 Receives Clearance 72 Successfully Tested 72 Expands Portfolio 72 Obtains Exclusive License 72 Develop Novel 72 Drug Candidate 72 Expands Capacity 72 Introduces Next Generation 72 Receives Milestone Payment 72 Announces Initiation 72 Obtains License 72 Successfully Tests 72 Introduces Enhanced 72 Unveils Revolutionary 72 Scientists Develop 72 Presents Positive 72 Announce Licensing Agreement 72 Shows Promise 72 Files Patent Infringement 72 Enrolls First 72 Collaborators Publish 72 Presents Preclinical Data 72 Present Preclinical Data 72 Submits NDA 71 Initiates Enrollment 71 Demonstrates Significant 71 Therapeutic Competitors Companies 71 Announces Publication 71 Signs Licensing Agreement 71 Researchers Develop 71 Announces Favorable 71 Obtains Approval 71 Initiates Clinical 71 Signs License Agreement 71 Manufacturer Selects 71 Unveils Breakthrough 71 Delivers Next Generation 71 Reduces Risk 71 Taglich Brothers Initiates Coverage 71 Expands Capabilities 71 Settle Patent Litigation 71 Subsidiary Enters 71 Launches Next Generation 71 Patent Infringement Lawsuit Against 71 Receives Favorable 71 Significantly Increases 71 Significantly Improves 71 Study Demonstrates 71 Significantly Reduces 71 Unveils Innovative 71 Unveils Newest 71 Announces Presentation 71 Completes Dosing 71 Strengthens Its 70 High Growth Forecasted 70 Patent Infringement Lawsuit 70 Announce Availability 70 Licenses Novel 70 Commercialize 70 Introduces Innovative 70 Provides Update Regarding 70 Expands Presence 70 Study Identifies 70 ANADIGICS Announces 70 Obtains Patent 70 Secures Patent 70 Provides Comprehensive 70 Receives Approvable Letter 70 Successfully Demonstrates 70 Novel Oral 70 Submits IND 70 Receives Favorable Ruling 70 Introduces Powerful 70 Flagship Product 70 Secures Financing 70 Signs Agreements 70 Shows Promising 70 Patents Issued 70 Successfully Concludes 70 Collaborators Present 70 Platform Enables 70 Jointly Develop 70 Successfully Completes 70 Initiates Dosing 70 Accelerate Commercialization 70 Expand Relationship 70 Presents Positive Preclinical 70 Acquires Exclusive 69 Unveils Latest 69 Announces Divestiture 69 Secures Contract 69 Provides Guidance 69 Launches Enhanced 69 Demonstrates Interoperability 69 Extends Capabilities 69 Wins Patent Infringement 69 Demonstrates Potential 69 Receives CE Marking 69 Receives Notification 69 Meets Primary Endpoint 69 Report Examines 69 Licenses Patents 69 Unveils Groundbreaking 69 Inks Licensing Deal 69 Patent Lawsuit 69 Achieves Certification 69 Enters Agreement 69 FDA Okays 69 Extends Collaboration 69 Announces Dismissal 69 Penetrates 69 Successfully Demonstrate 69 Receives NASDAQ 69 Unveils Next Generation 69 IND Application 69 Introduces Novel 69 Completes Divestiture 69 Study Confirms 69 Settles Patent Litigation 69 Patent Broadly Covering 69 Voluntarily Withdraws 69 Markets Examine 69 Board Authorizes 69 Receives Certification 69 Expands Scope 69 Successfully Completes Phase 69 Receives Order 69 Finalizes Acquisition 69 Expands Internationally 69 Announce Merger Agreement 69 Announces Successful Completion 69 Completes Installation 69 Validates 69 Settle Patent Dispute 69 Awarded Contracts 69 Discontinues 69 Expands Availability 69 Holds Promise 69 Tumor Targeting 69 Data Suggest 69 Achieves ISO #:# Certification [002] 69 Strengthens Balance Sheet 69 Inventors Develop 69 Toshiba Develops 69 Showcases Innovative 68 Successfully Launches 68 Settles Patent Dispute 68 Complies With 68 Establish Joint Venture 68 Boosts Productivity 68 Patents Upheld 68 Clinical Trial Evaluating 68 Awarded GSA Schedule 68 Subsidiary Signs 68 Patent Dispute 68 Q2 Loss Narrows 68 Gene Expression Analysis 68 Extends Leadership 68 Patent Lawsuit Against 68 Completes Transition 68 FDA Approvals 68 Regains Compliance 68 Jumps Higher 68 Announces Availability 68 Updates Guidance 68 Completes Tender Offer 68 DayTradersDigest.com Profiles 68 Receives Commitment 68 Patent Infringement Case 68 Provides Shareholder 68 Dramatically Increases 68 Milestone Payment 68 Announces Effective Date 68 NEC Develops 68 Releases Next Generation 68 Receives Orphan Drug 68 Outlines Strategy 68 Study Indicates 68 Receives Funding 68 Doubles Capacity 68 Achieves Breakthrough 68 Enters Into Exclusive 68 Restructures Operations 68 Enters Into Licensing Agreement 68 Receives Tentative Approval 68 Eliminates Need 68 Secures Funding 68 Announces Organizational Changes 68 Streamlines Operations 68 Further Strengthens 68 Protects Against 68 Complete Merger 68 Proves Effective 68 Commences Phase 68 Files Shelf Registration Statement 68 Demonstrates Superior 68 Demonstrates Commitment 68 Further Validates 68 Delivers Comprehensive 68 Takes Delivery 68 Establishes Joint Venture 68 Q1 Loss Widens 68 Migraine Drug 68 Q3 Loss Narrows 68 Reports Positive 68 TVS Diodes 68 Significantly Enhances 68 Clinical Study Shows 68 Delivers Enhanced 68 Continues Momentum 68 Q1 Loss Narrows 68 Preclinical Data 68 Accelerates Growth 68 Receives Notice 68 Completes Purchase Of 68 Newly Identified 68 Provide Comprehensive 68 Assigned Patent 68 Host Webcast 68 Other OTC MNDP 68 Reconfirms 68 Announce Joint Venture 68 AnaSpec Introduces 68 Announces Definitive Agreement 68 Collaborates With 68 Patients Enrolled 67 Completes Successful 67 Subsidiary Awarded 67 Osteoporosis Drug 67 Milestone Achieved 67 FDA Accepts 67 Fortifies 67 Presents Preclinical 67 Develop Innovative 67 First Patient Treated 67 Systemic Delivery 67 Receives Regulatory 67 Achieves Profitability 67 Motorola Invests 67 Achieves Record 67 Submits Response 67 Enters Into License Agreement 67 BioSante Pharmaceuticals Announces 67 Successfully Completed 67 Proves Successful 67 Becomes Exclusive Distributor 67 Secures Additional 67 Announce Initiation 67 Achieves Record Sales 67 Small Molecule 67 Phase III Clinical Trial 67 Starts Shipping 67 Releases Enhanced 67 Submits Biologics License Application 67 Launches Innovative 67 Q3 Loss Widens 67 FDA Clearance 67 Patent Upheld 67 Explore Strategic Alternatives 67 Expand Presence 67 Pending Acquisition 67 Acquire Assets 67 Receives Positive 67 Announces Enhancements 67 Enhances User Experience 67 Restructures Debt 67 Fiscal Quarter Results 67 Demonstrates Ability 67 COMUNICADO 67 Formalizes 67 Molecular Diagnostic Test 67 Strengthens Leadership 67 Terminates Contract 67 Exclusive License 67 Settles Litigation 67 Successfully Deploys 67 Single Dose 67 Announce Settlement 67 RNAi Therapeutics 67 Sinks Lower 67 Phase III Trial 67 Mutually Agree 67 Completes Acquisitions 67 Acacia Subsidiary 67 Unveils Powerful 67 Announces Expanded 67 Q4 Loss Narrows 67 Jointly Launch 67 PRN FDA Approves 67 Dry Powder Inhalers 67 Receives Recognition 67 Therapeutic Competitors companiesandmarkets.com adEgemonye 67 Leadership Position 67 Continues Aggressive 67 Subsidiary Enters Into 67 Announces Tentative Approval 67 Announce Agreement 67 Proven Effective 67 Announces Termination 67 Regains Full 67 Jointly Offer 67 Q2 Loss Widens 67 Wins Contract 67 Expanded Indication 67 Arthritis Drug 67 Provides Unprecedented 67 Successfully Demonstrated 67 Extend Collaboration 67 Improves Efficiency 67 Strengthens Presence 67 Carbon Nanotube Based 66 Achieves Primary Endpoint 66 Develops Breakthrough 66 Study Evaluating 66 Increases Efficiency 66 Expands Commitment 66 Study Proves 66 Acquires Controlling Interest 66 Widely Used 66 Inhibits 66 Improves Productivity 66 BOTHELL Wash. Business Wire 66 MONSTERSTOX.COM Monsterstox.com 66 CybeRelease Decliners 66 Host Webinar 66 Commercially Available 66 Improves Survival 66 Significantly Expands 66 Granted Orphan Drug 66 Enters Negotiations 66 Announces Poster Presentations 66 Debuts Next Generation 66 Expands Distribution 66 Extends Reach 66 Jointly Announce 66 Reduces Size 66 Non Invasive 66 Vaccine Adjuvant 66 Reports Preclinical Data 66 Provides Updates 66 Acquire Privately Held 66 Effectively Treats 66 Patented Technology 66 Multi Billion Dollar 66 Sharpens Focus 66 Issues Guidance 66 Begins Dosing 66 Announces Formation 66 Canaccord Genuity Maintains Hold 66 & Sullivan Recognizes 66 Receives Approval 66 Submits Proposal 66 Ships #th 66 Transdermal Patch 66 Transdermal Drug 66 Attains 66 Amends Agreement 66 Earns Milestone Payment 66 Investigational Compound 66 Patient Enrollment 66 Successfully Delivers 66 Taro Receives 66 Provides Detailed 66 Successfully Integrates 66 MarketsandMarkets Global 66 Study Validates 66 Method Developed 66 visit http:/www.mannkindcorp.com 66 Introduces Expanded 66 Regains Compliance With 66 Enters Into Agreement 66 Asthma Treatment 66 ORLive Presents 66 Files Patents 66 Acquisition Strengthens 66 Subsidiary Acquires 66 Successfully Deployed 66 Unsolicited Proposal From 66 Strengthens Commitment 66 Q4 Loss Widens 66 Prolongs Survival 66 Blood Clotting 66 Settle Litigation 66 Awarded Multi 66 Epilepsy Drug 66 Regains NASDAQ 66 Celebrates Opening 66 RNAi Therapeutic 66 Mylan Receives Approval 66 Nasdaq SMTS develops manufactures 66 Phase 2a Trial 66 Announces Launch 66 Announces Favorable Ruling 66 Agilent Technologies Introduces 66 Revolutionizes 66 Product Lines 66 Named Exclusive Distributor 66 Could Revolutionize 66 Delivers Unprecedented 66 Protein Biomarkers 66 Wins Summary Judgment 66 Confirms Commitment 66 Announce Exclusive 66 Announces Addition 66 Patent Infringement Litigation 66 Generic Versions 66 BioElectronics Announces 66 Successfully Complete 66 Deliver Presentation 66 Drug Shows Promise 66 Bullish Speculation 66 Inc Therapeutic Competitors 66 Announces Stockholder Approval 66 Q1 Profit Surges 66 Launches Unique 66 IrelandRESEARCH AND MARKETS 66 Media NewsEdge STOCK MARKETING 66 WorldHeart Announces 66 Product Offerings 66 Implant Sciences Announces 66 Competition G.1 66 Announces Dosing 66 Announce Interoperability 66 Seasonal Influenza Vaccine 66 Completes Initial 66 Lupus Drug 66 Expands Into 66 Doubles Size 66 Molecular Mechanism 66 Provides Preliminary 66 Accelerates Expansion 66 Appoints Experienced 66 BioElectronics Corporation Announces 66 Rheumatoid Arthritis Drug 66 OTCBB CAEH 66 Milestone Reached 66 Inks Pact 66 Wins Approval 66 Continues Expansion 66 Earnings Postmortem 66 Initiates Phase III 66 Phase IIb Trial 66 Introduce Next Generation 66 Enter Into 66 Welcomes Analyst Initiation 66 Reduces Debt 66 Awarded Contract 65 Buys Majority Stake 65 Spins Out 65 Enters Strategic 65 Commences Operations 65 platform HDL Mimetic 65 Initiates Phase 65 PRODUCT SOURCE 65 Deliver Powerful 65 Files Investigational 65 NDA Submission 65 Amplifies 65 Announces Commencement 65 Expands Deployment 65 AUDIO PROVIDED BY 65 Explores Strategic Alternatives 65 Fungal Infections 65 Voluntarily Withdraw 65 Q2 Profit Surges 65 Inks MOU 65 Teva Provides Update 65 Expands Globally 65 Veeco Introduces 65 Acquires Remaining Interest 65 Selects Camstar 65 Gout Drug 65 Report Identifies 65 Researchers Identify 65 Announce Licensing 65 Solution Delivers 65 Magazine Recognizes 65 Differentiates 65 Generic Version 65 Completes Patient Enrolment 65 Gets Approval 65 Broadens Its 65 Announces Resumption 65 Announces Definitive Agreements 65 Expands Functionality 65 Host Fourth Quarter 65 Expands Reach 65 Obtains FDA 65 Obtains Exclusive Rights 65 Helps Reduce 65 Randomized Trials 65 Spins Off 65 Lowers Guidance 65 Announces Filing 65 Reduces Cost 65 Puts Purchased 65 Lanthanum Carbonate 65 Reveals Positive 65 Quadruples 65 Begin Clinical Trials 65 Achieves Highest 65 Acquires Assets 65 Oral Interferon 65 Develops Next Generation 65 Successful Completion 65 Closes Sale 65 Enters Into Strategic 65 Shares Soar 65 Showcases Latest 65 BIOTECHNOLOGY SOURCE 65 Launches Redesigned Website 65 Completes Merger With 65 Increases Capacity 65 submitted Biologics License 65 Enables Rapid 65 Updates Shareholders 65 Cypher Sirolimus 65 Showcases Next Generation 65 siRNA Delivery 65 Finalize Joint Venture 65 Technological Advances 65 Builds Momentum 65 Sign Reseller Agreement 65 Successfully Launched 65 Fujitsu Develops 65 Subsidiary Wins 65 Obtains Exclusive 65 Increases Productivity 65 Photovoltaic Module 65 Increases Presence 65 Demonstrates Positive 65 Market Penetration 65 News Unternehmensnachrichten 65 Receives Positive Opinion 65 Introduces Groundbreaking 65 Planned Acquisition 65 Stock Soars 65 Helps Predict 65 Acquire Controlling Interest 65 LYON France BUSINESS WIRE 65 Expands Footprint 65 Reaffirms Commitment 65 Bone Grafts 65 Signs Merger Agreement 65 Guides Inline 65 Revises Guidance 65 VentiRx Pharmaceuticals 65 Retains CCG Investor Relations 65 Settle Patent 65 Announce Definitive Agreement 65 Completes Purchase 65 Delivers Breakthrough 65 TriCo Bancshares Announces 65 Files Provisional 65 Announces Expansion 65 技术 65 의 은 65 Lung Cancer Drug 65 Anti Tumor 65 Identifies Key 65 Pivotal Study 65 Receives Confirmation 65 Completes Reverse Merger 65 Pharmaceuticals Initiates 65 Announces Receipt 65 Enables Easy 65 Demonstrates Long Term 65 Altera Ships 65 Licensing Pact 65 Appoints Seasoned 65 Inc. OTCBB MNDP 65 Refocuses 65 Lays Keel 65 Shares Surge 65 Expand Capacity 65 Receives Marketing Authorization 65 Guidelines Recommend 65 Completes Integration 65 CONFERENCE CALLS SOURCE 65 Canaccord Genuity Reiterates Buy 65 Reduces Costs 65 BIOLASE Announces 65 Ink Pact 65 Seeks Approval 65 Finalizes Purchase 65 Settles Patent Suit 65 STMicroelectronics Unveils 65 StockSource.us Reports 65 Acquirer Company 65 Therapeutic Competitors Report 65 Exploring Strategic Alternatives 65 Positions Itself 65 Increases Commitment 65 Receives Delisting Notice 65 Patent Infringement 65 Achieves ISO # 65 Realigns 65 Signs Lease 65 Shares Climb 65 SWOT Analysis Aarkstore Enterprise 65 Releases Latest 65 Expands Relationship With 65 Proudly Announces 65 Successfully Closes 65 Demonstrate Innovative 65 Novel Vaccine 65 Outperforms 65 Software Simplifies 65 Extends Commitment 65 Announces Signing 65 Officially Launches 65 Furthers 65 Balloon Catheters 65 Kinase Inhibitor 65 Exercises Option 65 Genes Involved 65 FDA Warns 65 Introduces Unique 65 Submits Supplemental 65 * vwd PRN 65 Imaging Technique 65 Authorizes Additional 65 Concludes Successful 65 Controlled Clinical Trial 65 Study Shows Benefits 65 Confirms Receipt 65 Thewallstreetleader.com Profiles 65 Unveils Enhanced 65 Announce Receipt 65 STRATEGY ANALYTICS 65 Shows Promise Against 65 Commenced Against 65 Announces Effectiveness 65 Announce Commencement 65 Improves Accuracy 65 Establishes Subsidiary 65 Announces Acquisition 65 Osteoporosis Treatment 65 Licensing Deal 65 Offers Affordable 64 OTCBB ILNS 64 Completes Expansion 64 INDUSTRY ASSESSMENTS 64 Successfully Completes Tender Offer 64 Rapidly Growing 64 Psoriasis Drug 64 Laboratory pH Electrodes 64 Executes Agreement 64 Technicals Showing Bearish 64 Completes Merger 64 Rated Speculative Buy 64 Receives ISO #:# [002] 64 Patent Infringement Suit 64 Cardiovascular Monitoring 64 Bearish Speculation 64 Attracting Bullish Investors 64 Patent Infringement Suit Against 64 Signs Distribution 64 Confirms Efficacy 64 Shareholders Approve Acquisition 64 Patent Filings 64 Launches Groundbreaking 64 Enters Into Settlement Agreement 64 Reduce Risk 64 Announce Completion 64 Treating Chronic 64 Establishes Presence 64 Initiate Clinical Trial 64 Low Dose 64 Announces Additions 64 Posts Strong 64 Study Reinforces 64 Identifies Potential 64 Receives Fast Track 64 Reinforces Commitment 64 Offers Unprecedented 64 Uses Thereof 64 Announce Formation 64 Shares Plummet 64 & Sullivan Lauds 64 Finalizes Agreement 64 Reports Receipt 64 Expand Into 64 Monoclonal Antibody 64 Continues Rapid 64 Nanophase Announces 64 Reach Settlement Agreement 64 Antimicrobial Coating 64 Mass.MA 64 Reportlinker Adds Global 64 Achieves Prestigious 64 Unveils Upgraded 64 Closes Acquisition 64 Awarded Prestigious 64 Q4 Profit Decreases 64 Unveils Expanded 64 Q4 Profit Surges 64 Completes Reorganization 64 Enters Joint Venture 64 Markettelegraph.com 64 Drug Resistant 64 INC PRESENTS 64 Announces Adjournment 64 TheWallStreetLeader.com Profiles 64 Awarded Qualifying Therapeutic 64 CALLS SOURCE 64 Speeds Up 64 Provides Updated 64 Study Shows Significant 64 Nasdaq XTLB 64 Testing Capabilities 64 OTCBB CVDT 64 Activity Alert 64 Initiates Voluntary Recall 64 NASDAQ Listing Requirements 64 Gets Clearance 64 Accelerate Adoption 64 Earns Certification 64 Inventor Develops 64 Momentum Continues 64 Momentum Grows 64 Consummates 64 Has Spiked 64 Regains Nasdaq 64 Phase IIb Clinical Trial 64 otcstockexchange.com 64 Reports Significantly Improved 64 Repositions 64 Receives Approvals 64 IND Filing 64 Alert Technicals Showing Bearish 64 Achieves ISO 64 Glucose Monitoring 64 Announces Keynote Speakers 64 Subsidiary Awarded Contract 64 Reinforces 64 Dramatically Expands 64 Gets Favorable Ruling 64 Moves Towards 64 Presents Webinar 64 Underscores Commitment 64 Forges Partnership 64 PAUL Minn.MN 64 Orally Active 64 Finalizes Sale 64 이 을 64 Patent Suit 64 Being Studied 64 Biotech Firm 64 Smallpox Vaccine 64 Combination REOLYSIN R 64 Achieves Record Revenue 64 Q4 Profit Soars 64 Closes Merger 64 Uses SolidWorks 64 Breakthroughstocks.net EXPLOSIVE news 64 Blood Thinner 64 Hip Prosthesis 64 Adopts Cadence 64 Forges Strategic 64 Obtains 64 Technological Developments II 64 Trading Activity 64 Demonstrates Next Generation 64 Symmetricom Announces 64 Expert Discusses 64 Gliadel R 64 Calls Purchased 64 Infringes 64 Offers Enhanced 64 Lowers Risk 64 Drug Fails 64 Expand Capabilities 64 Announces Preliminary 64 Enables Faster 64 Introduces 64 Phase IIa Clinical Trial 64 ARRIS Announces 64 DCSW# DCSW# 64 Options Trader Alert 64 Recombinant Human 64 Announces Positive 64 Successfully Treats 64 Extends Tender Offer 64 研究 64 Daytradersdigest.com 64 AGREEMENTS SOURCE 64 에 을 64 Acquire Majority Stake 64 Commence Phase 64 Achieves Positive 64 Closes Acquisition Of 64 Guidelines Issued 64 Clinical Evaluation 64 Coverage Initiated 64 Webcast Presentations 64 Cardiovascular Prosthetic Devices 64 Launches Breakthrough 64 Settles Patent 64 Inc. Gengsheng develops 64 Study Examines 64 BAG# BAG# BAG# BAG# 64 Vascular Inflammation 64 Protease Inhibitor 64 Reports Profitable 64 FDA Warns Against 64 SABER ™ 64 STERIS Corporation Announces 64 Clinical Outcome 64 Consolidates Operations 64 Post Earnings Checkup 64 Files Voluntary 64 Anounces 64 Improves Outcomes 64 Initiate Phase III 64 Unlocks 64 Q1 Profit Plunges 64 Announce Reseller Agreement 64 Commercialize Novel 64 Phase 1b Clinical Trial 64 Nasdaq Listing Requirements 64 Extend Partnership 64 Enters Into Collaboration 64 Demonstrates Sustained 64 Achieve Significant 64 Terminate Merger Agreement 64 PPD Declares 64 Announces Successful 64 Pivotal Trial 64 Submits Bid 64 Confirms Filing 64 Completes Acquisition 64 Receives ISO #:# [001] 64 Net Loss Narrows 64 Diversifies 64 Ramps Up Production 64 Novel Method 64 Receives Notice From 64 Cuts Costs 64 researches develops licenses 64 OTC MNDP 64 中国 的 64 Reacquires 64 Reaffirms FY# Outlook 64 Significantly Improved 64 Lithium Battery 64 Dry Powder Inhaler 64 Award Recognises 64 Induces 64 Directors Authorizes 64 Patent Suit Against 64 Provides Enhanced 64 Awarded GSA 64 Announce Launch 64 Demonstrates Improved 64 Net Loss Widens 64 Study Suggests 64 Announcement acc 64 Achieves ISO #:# Certification [001] 64 Signs Reseller Agreement 64 Bullish Engulfing Pattern 64 Anthrax Toxin 64 Announces Webcast 64 Panasonic Develops 64 Buy Privately Held 64 PROFILE CO 64 Updates Outlooks 64 Restate Financials 64 Demonstrate Latest 64 Demonstrates Innovative 64 Cancer Treatments 64 Host Third Quarter 64 Insulin Pen 64 Announces Discontinuation 64 Addresses Growing 64 Stock Downgraded 64 Stem Cell Treatment 64 Achieves Record Growth 64 Milestone Payments 64 Options Activity 63 Files Annual Report 63 MorphoSys AG FSE MOR 63 Host Second Quarter 63 Announce Successful Completion 63 Oral Fingolimod 63 Introduces Affordable 63 Completes Sale 63 Deliver Next Generation 63 Releases Latest Version 63 Enable Faster 63 Successfully Completes Acquisition 63 Receives CE 63 Alert Technicals Showing Bullish 63 Commences Phase III 63 Bullish Average Crossover 63 Announces Spin Off 63 Anti Tumor Activity 63 Broadens 63 Expands Scientific Advisory 63 Files Shelf Registration 63 Well Tolerated 63 Nasopharyngeal Electrodes Needle Electrodes 63 Survey Ranks 63 Distribution Pact 63 Solution Achieves 63 Q1 Profit Soars 63 Renews Agreement 63 Board Unanimously Rejects 63 RENO NV #/#/# 63 Announces Voluntary Recall 63 Secures 63 Technicals Showing Bullish 63 Nears Completion 63 Achieves Milestones 63 Reaffirms Guidance 63 STMicroelectronics Introduces 63 contain Totally Degradable 63 Conjugate 63 Dramatically Improves 63 Carries Out 63 Narrows Loss 63 Highly Integrated 63 DURHAM NC Business Wire 63 Publishes 63 Reinforces Leadership 63 Flamel Technologies Announces 63 Broadens Scope 63 Receives Prestigious 63 Scientists Identify 63 Reduces Workforce 63 Enlarges 63 Ventures Invests 63 Receives Authorization 63 TRADESHOW SOURCE 63 Finalize Agreement 63 ADDING MULTIMEDIA 63 Patent Ruling 63 Stays Neutral 63 COMPLETES ACQUISITION OF 63 Inks Deals 63 Raytheon Delivers 63 Revises FY# Outlook 63 Avian Flu Vaccine 63 Wizzard Software Announces 63 Hsp# Inhibitor 63 것이다 63 Accelerates 63 Receive Milestone Payment 63 Expansion Into 63 Earns Coveted 63 Sees Significant 63 Successfully Treated